2 completed, 1 active not recruiting. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Active not recruiting 1 |
Follow Newly Diagnosed: new trials by email Literature Review of Newly Diagnosed trials Research Report on Newly Diagnosed
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Zanubrutinib, Lenalidomide, Obinutuzumab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 | Active not recruiting | Institute of Hematology & Blood Diseases Hospital, China | 30 | 2024-01-01 | 2024-08-09 |
| Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1, MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 2-Arm A, MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) + azacitidine + venetoclax - Leukemia, Myeloid | Phase 1 | Completed | Molecular Partners AG | 80 | 2022-12-29 | 2026-09-25 |
| Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Selinexor, Temozolomide, Generic Radiation therapy (RT) - Gliosarcoma, Newly Diagnosed | Phase 1 | Completed | National Cancer Institute (NCI) | 11 | 2020-07-07 | 2026-10-27 |
Glioblastoma (1) · Gliosarcoma (1) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1)
Neoplasms (3) · Neoplasms by Histologic Type (3) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Astrocytoma (1) · Chronic Disease (1) · Disease Attributes (1) · Glioma (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia (1) · Leukemia, B-Cell (1) · Leukemia, Lymphoid (1) · Lymphatic Diseases (1) · Lymphoproliferative Disorders (1)
Azacitidine (1) · Lenalidomide (1) · Loperamide (1) · Olanzapine (1) · Salts (1) · Serotonin Antagonists (1) · Sodium Chloride (1) · Temozolomide (1) · obinutuzumab (1) · selinexor (1) · venetoclax (1) · zanubrutinib (1)
Institute of Hematology & Blood Diseases Hospital, China (1) · Molecular Partners AG (1) · National Cancer Institute (NCI) (1)
China (1) · France (1) · Lithuania (1) · Netherlands (1) · Switzerland (1) · United States (1)
2023 (1)